TOP TIERMARKET NEWSWIRE
Movers explained · October 30, 2026

Why Is AGIOS PHARMACEUTICAL (AGIO) Stock Down Today?

By the Top Tier Newswire AI Desk · July 22, 2026 at 12:10 AM ET · reviewed against 7 wire stories

AGIOS PHARMACEUTICAL (AGIO) is down -17.94% in the latest session. Our newswire has captured 7 stories on AGIO across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

AGIO stock is down 6.74% at $37.36 following the company’s announcement that it will discontinue development of tebapivat for sickle cell disease after a Phase 2 trial. The decision shifts focus to mitapivat, which is under FDA Priority Review for its sNDA, but the news has caused concern among investors. The stock has fallen for multiple reasons, including the termination of a key program and the broader market context.

What Happened

Agios Pharmaceuticals announced it will stop development of tebapivat, an oral pyruvate kinase activator, for sickle cell disease after the Phase 2 trial failed to meet expectations. The 12-week study involved 59 patients, and the company cited the outcome as the reason for discontinuation. Mitapivat remains a key focus, with a PDUFA goal date of Nov. 1, 2026. Despite this, the decision to abandon tebapivat has raised questions about the company’s pipeline depth and future growth prospects. The stock has dropped sharply in response, reflecting investor disappointment.

What The Data Shows

AGIO has fallen 7.6% over the past eight sessions, from $40.96 to $37.85. The stock currently trades within its 52-week range of $22.24 to $46.00. The company reported a revenue increase of 78.3% in the trailing twelve months but remains unprofitable with an EPS of -7.25. The recent insider transaction includes a $151K sale by the Chief Medical Officer on July 1, 2026. Congressional activity includes a buy of $1,001, $15,000 by Rep. Gilbert Cisneros on December 11, 2025.

What To Watch

Investors should monitor the FDA’s decision on mitapivat’s sNDA, with a PDUFA date of Nov. 1, 2026. Broader market sentiment and coverage from analysts will also be key as the stock continues to face pressure.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

AGIO by the numbers

Last: $30.55Session: -17.94%7 sessions: -4.96%Coverage: 7 stories / 5 sourcesAI sentiment: 52/100 (mixed)Mkt cap: $2.4B52w: $22.24 to $46.00
AGIO · today's session (5-min) · -12.33% vs prior close · updated 9:32 AM ET
$31.69$34.61$37.54prev close $37.23$32.647:10 AM7:45 AM8:20 AM8:55 AM9:30 AM7:10 AM · $36.007:20 AM · $34.507:30 AM · $34.957:40 AM · $34.507:45 AM · $34.017:50 AM · $34.508:00 AM · $34.008:05 AM · $33.858:30 AM · $32.748:35 AM · $32.859:05 AM · $32.569:15 AM · $32.079:20 AM · $32.009:25 AM · $32.009:30 AM · $32.64
AI sentiment, last 36h · averaged over 7 stories · 52/100 neutral
AI sentiment 52/100 (neutral)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 7 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agonowThe Fly · sentiment 63 · Agios Pharmaceuticals assumed with a Buy at H.C. WainwrightThe Fly · 63Agios Pharmaceuticals assumed with a Buy at H.C. WainwrightGuruFocus · sentiment 63 · AGIO Assumes Buy Rating by HC Wainwright & Co. -- Price Target at $55GuruFocus · 63AGIO Assumes Buy Rating by HC Wainwright & Co. -- Price Target at $55StockTitan · sentiment 63 · Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDAStockTitan · 63Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Diseas…The Fly · sentiment 52 · Agios Pharmaceuticals announces new PDUFA goal date for mitapivat sNDAThe Fly · 52Agios Pharmaceuticals announces new PDUFA goal date for mitapivat sNDASeeking Alpha · sentiment 34 · Agios falls on review extension for Pyrukynd label expansionSeeking Alpha · 34Agios falls on review extension for Pyrukynd label expansionMarketWatch · sentiment 34 · Agios Pharmaceuticals Shares Fall on FDA Review ExtensionMarketWatch · 34Agios Pharmaceuticals Shares Fall on FDA Review ExtensionThe Fly · sentiment 52 · Agios FDA review delay just ‘timing setback,’ says H.C. WainwrightThe Fly · 52Agios FDA review delay just ‘timing setback,’ says H.C. Wainwright
7m agoThe FlyNEUTRAL 52Analyst

Agios FDA review delay just ‘timing setback,’ says H.C. Wainwright

36m agoMarketWatchBEARISH 34General

Agios Pharmaceuticals Shares Fall on FDA Review Extension

The FDA in early October requested additional information to evaluate whether a risk evaluation and mitigation strategy is necessary for the drug. After Agio submitted a response, including about nine months of updated safety data from other trials, the FDA issued its three-month review extension.

2h agoSeeking AlphaBEARISH 34General

Agios falls on review extension for Pyrukynd label expansion

Agios Pharmaceuticals (AGIO) stock fell after the FDA delayed the review of the firm

4h agoThe FlyNEUTRAL 52Product/PR

Agios Pharmaceuticals announces new PDUFA goal date for mitapivat sNDA

4h agoStockTitanBULLISH 63Product/PR

Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA

1d agoGuruFocusBULLISH 63Analyst

AGIO Assumes Buy Rating by HC Wainwright & Co. -- Price Target at $55

1d agoThe FlyBULLISH 63Analyst

Agios Pharmaceuticals assumed with a Buy at H.C. Wainwright

Frequently asked questions

Why is AGIO stock down today?

AGIOS PHARMACEUTICAL (AGIO) is down -17.94% in the latest session. Our newswire has captured 7 stories on AGIO across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100). The most recent driver: "Agios FDA review delay just ‘timing setback,’ says H.C. Wainwright" (The Fly).

Is AGIO a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of AGIO coverage reads 52/100 over 7 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.

More moves explained today

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on AGIO: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.